7Baggers

We provide you with 20 years of free, institutional-grade data for ELEV stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ELEV. Explore the full financial landscape of ELEV stock.

Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
NameActionSharesAvg PriceAmountReported Date
Login to see more insider transactions
The information provided in this report about ELEV stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Elevation Oncology Inc
(NASDAQ:ELEV) 

ELEV stock logo

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a cl...

Founded: 2019
CEO / Founder: Shawn Leland 
Sector:
Industry:

Share this website to your friends